摘要
目的:探究贝伐珠单抗联合阿法替尼治疗非小细胞肺癌临床疗效。方法:研究对象选取我院收治的非小细胞肺癌患者98例,随机分为对照组(49例)及实验组(49例),对照组给予常规一线化疗(培美曲塞^+卡铂)治疗,实验组在其基础上加用贝伐珠单抗联合阿法替尼进行治疗,观察两组治疗疗效,记录并比较两组治疗前后免疫功能、血管新生相关指标及不良反应发生率。结果:两组治疗前CD3^+、CD4^+、CD4^+/CD8^+、IgG、IgM、IgA及VEGF、BFGF、HDGF水平比较,差异无统计学意义(P>0.05);治疗后,两组均降低,且实验组CD3^+、CD4^+、CD4^+/CD8^+、IgG、IgM、IgA水平高于对照组,VEGF、BFGF、HDGF水平低于对照组,实验组治疗有效率高于对照组,差异均具有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:贝伐珠单抗联合阿法替尼能有效提高非小细胞肺癌患者治疗疗效,抑制其血管新生因子的表达,提高患者免疫功能且不增加患者不良反应,值得临床推广。
Objective:To investigate the clinical efficacy of bevacizumab combined with afatinib in the treatment of non-small cell lung cancer.Methods:Ninety-eight patients with non-small cell lung cancer admitted to our hospital from December 2014 to December 2017 were randomly divided into the control group(49 cases)and the experimental group(49 cases).The group was treated with conventional first-line chemotherapy(pemetrexed plus carboplatin).The experimental group was treated with bevacizumab plus afatinib.The therapeutic effects of the two groups were observed.Immune function,angiogenesis related indicators and incidence of adverse reactions.Results:The levels of CD3^+,CD4^+,CD4^+/CD8^+,IgG,IgM,IgA,VEGF,BFGF and HDGF were not significantly different between the two groups(P >0.05).After treatment,both groups were reduced,and the experimental group the levels of CD3^+,CD4^+,CD4^+/CD8^+,IgG,IgM and IgA were significantly higher than those of the control group.The levels of VEGF,BFGF and HDGF were significantly lower than those of the control group.The effective rate of the experimental group was significantly higher than that of the control group(P<0.05).There was no significant difference in the rate(P >0.05).Conclusion:Bevacizumab combined with afatinib can effectively improve the therapeutic effect of patients with non-small cell lung cancer.It has been the expression of angiogenic factors,improve the immune function of patients and increase the adverse reactions of patients,which is worthy of clinical promotion.
作者
赵仔君
谷晓媛
张为强
周聆
ZHAO Zi-jun;GU Xiao-yuan;ZHANG Wei-qiang;ZHOU Ling(Department of Oncology,Shibei Hospital,Jing'an District,Shanghai 200435)
出处
《海南医学院学报》
CAS
2019年第2期129-132,共4页
Journal of Hainan Medical University
基金
上海市卫生和计划生育委员会项目(20144Y0047)~~
